Daniel S. Levine

Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.

[Daniel S. Levine @dslevine]

Ryan Beal @DyveBio discusses why acidity is an overlooked but foundational target in oncology, how its delivery technology may overcome the limitations of oral bicarbonate dosing, and indications beyond cancer that the company is pursuing.
https://t.co/v3xecInGMX

[Daniel S. Levine @dslevine]

Steven Ringel, founder and CEO of Nome, discusses helping families and patient groups evaluate genetic-medicine options, shape development plans, and connect with partners to advance individualized therapies toward the clinic. @globalgenes #RARECast

https://t.co/USWgcKEItu

[Daniel S. Levine @dslevine]

Catharina Svanborg @HamletBioPharma , discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue.

https://t.co/Zgyb7bpURd

[Daniel S. Levine @dslevine]

Catharina Svanborg @HamletBioPharma , discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue.

https://t.co/Zgyb7bpURd

[Daniel S. Levine @dslevine]

Per Lundin of Evox Therapeutics, discusses the promise and limitations of exosome-enabled gene editing, how Evox is prioritizing its pipeline, and what it will take to establish this emerging therapeutic strategy in the clinic. @GlobalGenes #RARECast
https://t.co/EU2wtHfOWT

[Daniel S. Levine @dslevine]

@ErikIngelsson @WaveLifeSci explains how an RNA-based approach to fat loss could reshape obesity treatment—by targeting the biology that regulates fat breakdown and redefining what success looks like.
https://t.co/AiwaLVNKnY

[Daniel S. Levine @dslevine]

Eric Scheeff, CSO of Idefine, discusses progress in building the scientific foundation for a treatment for the neurodevelopmental condition Kleefstra syndrome, the role of its patient community, and its work ahead. @globalgenes #RARECast
https://t.co/7mfeU6F1zz

[Daniel S. Levine @dslevine]

@Jack_Silb , CEO of Deck Bio, discusses the company’s efforts to create multi-target T-cell engagers that reach more cancer cells, reduce the likelihood that tumors will evade treatment, and minimize harm to healthy tissue.
https://t.co/D1sXCAwoQ5

[Daniel S. Levine @dslevine]

Julie Raskin, CEO of Congenital Hyperinsulinism International discusses how an NICU crisis gave rise to the organization and its global fight for better treatments. @globalgenes #RARECast
https://t.co/TKzR5TgcNv

[Daniel S. Levine @dslevine]

Sid Kerkar @AllerGeneAI on the company’s efforts to reset mast cells in people with severe allergies, the potential for mRNA and lipid nanoparticle delivery to simplify and broaden access to CAR-T therapy, and what it will take to advance the platform. https://t.co/ovgHXeoEQ2

[Daniel S. Levine @dslevine]

Here's what you may have missed in August from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
https://t.co/6mpMyXnZ8x

[Daniel S. Levine @dslevine]

Doug Love @annexonbio discusses Guillain-Barré syndrome, the limits of current nonspecific care, and Annexon’s targeted approach to stopping the complement-driven inflammatory cascade at its source.
https://t.co/U1axaTR1wt

[Daniel S. Levine @dslevine]

Mayank Gandhi, co-founder and CEO of @NEOKBio , discusses the company’s bispecific ADC platform, its two clinical programs, and its strategy to develop more selective therapies for patients with advanced solid tumors.

https://t.co/zZtAmRRD0E

[Daniel S. Levine @dslevine]

@R_Bokhari @MedicusLtd discusses the company’s effort to develop a localized, non-surgical treatment for people with Gorlin syndrome, and how the patch may induce tumor-cell death while limiting systemic exposure. @globalgenes.bsky.social #RARECast https://t.co/tf8zaWW0xG

[Daniel S. Levine @dslevine]

Alan Trounson Evinco discusses the company’s effort to develop NK cell-derived particles to cross the blood-brain barrier, curb neuroinflammation, and promote amyloid clearance in Alzheimer’s.
https://t.co/v8HAUh2LjE

[Daniel S. Levine @dslevine]

Could sickle cell be cured before birth? @pshangaris @KingsCollegeLon discusses the PERICLES Project and prenatal gene editing’s promise. @GlobalGenes #RARECast https://t.co/Q4WyMwigCi

[Daniel S. Levine @dslevine]

@GileadSciences CMO Dietmar Berger on using targeted acquisitions to build platforms across solid tumors, autoimmune disease, and viral threats.
https://t.co/LsrT0xPzbW

[Daniel S. Levine @dslevine]

Unexplained weakness isn’t just aging. @Myasthenia Gravis Association’s Allison Foss and @ClevelandClinic John Morren discuss red flags for late-onset neuromuscular disease and a new clinical diagnostic tool. @globalgenes #RARECast
https://t.co/u0Lklpd2DN

[Daniel S. Levine @dslevine]

Half of ischemic stroke patients face poor outcomes. Revalesio’s Greg Archambeau discusses how the company’s oxygenated saline therapy, RNS60, may help protect the brain after stroke, reduce tissue damage, and change the economics of stroke care.
https://t.co/xJngeA1ggw

[Daniel S. Levine @dslevine]

.@ChiesiGRD has evolved through dealmaking, expanding into CRISPR and BBB tech—Giacomo Chiesi shares vision @GlobalGenes https://t.co/YuuwcxcA7m